$50.00
3.78% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$51.96
-0.44 0.84% 1M
+0.95 1.86% 6M
-4.02 7.18% YTD
+11.91 29.74% 1Y
+39.71 324.16% 3Y
+36.92 245.48% 5Y
+21.96 73.20% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.96 3.92%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Market capitalization $3.29b
Enterprise Value $3.22b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 24.75
P/S ratio (TTM) P/S ratio 25.24
P/B ratio (TTM) P/B ratio 149.19
Revenue growth (TTM) Revenue growth 68.06%
Revenue (TTM) Revenue $130.13m
EBIT (operating result TTM) EBIT $-265.51m
Free Cash Flow (TTM) Free Cash Flow $-113.88m
Cash position $320.57m
EPS (TTM) EPS $-4.36
P/E forward negative
P/S forward 17.70
EV/Sales forward 17.36
Short interest 11.10%
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

11x Buy
92%
1x Hold
8%

Analyst Opinions

12 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
130 130
68% 68%
100%
- Direct Costs 14 14
38% 38%
11%
116 116
73% 73%
89%
- Selling and Administrative Expenses 143 143
24% 24%
110%
- Research and Development Expense 237 237
77% 77%
182%
-264 -264
45% 45%
-203%
- Depreciation and Amortization 1.56 1.56
24% 24%
1%
EBIT (Operating Income) EBIT -266 -266
44% 44%
-204%
Net Profit -261 -261
41% 41%
-200%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
BOSTON, March 20, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it reacquired the rights to IMCIVREE® (setmelanotide) in China, including mainland China, Hong Kong and Macau, as the Company agreed to terminate it...
Neutral
GlobeNewsWire
15 days ago
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced it has received orphan drug designation from Japan's Ministry of Health, Labour and Welfare (MHLW) for setmelanotide as a treatment for acquired hypothal...
Neutral
GlobeNewsWire
16 days ago
New registry study to focus on impact of fatigue in people with craniopharyngioma New registry study to focus on impact of fatigue in people with craniopharyngioma
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 283
Founded 2008
Website www.rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today